297 related articles for article (PubMed ID: 25811801)
1. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
Oizel K; Gratas C; Nadaradjane A; Oliver L; Vallette FM; Pecqueur C
Cell Death Dis; 2015 Mar; 6(3):e1704. PubMed ID: 25811801
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
4. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
[TBL] [Abstract][Full Text] [Related]
5. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
6. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
7. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Sulkowski PL; Corso CD; Robinson ND; Scanlon SE; Purshouse KR; Bai H; Liu Y; Sundaram RK; Hegan DC; Fons NR; Breuer GA; Song Y; Mishra-Gorur K; De Feyter HM; de Graaf RA; Surovtseva YV; Kachman M; Halene S; Günel M; Glazer PM; Bindra RS
Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148839
[TBL] [Abstract][Full Text] [Related]
8. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
Kitagawa Y; Kobayashi A; Cahill DP; Wakimoto H; Tanaka S
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189102. PubMed ID: 38653436
[TBL] [Abstract][Full Text] [Related]
10. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
12. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
[TBL] [Abstract][Full Text] [Related]
15. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Neuro Oncol; 2018 Nov; 20(12):1573-1583. PubMed ID: 30020513
[TBL] [Abstract][Full Text] [Related]
16. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
[TBL] [Abstract][Full Text] [Related]
17. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
18. IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.
Zhao H; Meng L; Du P; Liao X; Mo X; Gong M; Chen J; Liao Y
Biol Res; 2024 May; 57(1):30. PubMed ID: 38760850
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
Schaap FG; French PJ; Bovée JV
Adv Anat Pathol; 2013 Jan; 20(1):32-8. PubMed ID: 23232569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
